India’s Prescription for Safety: Government Bans Over 200 ‘Irrational’ Medicines in Major Healthcare Crackdown

NEW DELHI — In a decisive move to overhaul the nation’s pharmaceutical landscape, the Indian government has banned 211 drug formulations between 2023 and 2025. Union Minister for Health and Family Welfare, Jagat Prakash Nadda, informed Parliament on February 5, 2026, that the prohibited list includes 172 medicines for human use and 39 veterinary drugs.

The crackdown primarily targets Fixed-Dose Combinations (FDCs)—medicines that package two or more active pharmaceutical ingredients into a single pill or injection. While FDCs can simplify treatment for chronic diseases like HIV or tuberculosis, regulators found that many of the banned combinations lacked scientific justification, posed significant health risks, and contributed to the global crisis of antimicrobial resistance.

The Surge in Regulation: A Three-Year Timeline

The intensity of India’s regulatory oversight has escalated dramatically. Following a period of zero prohibitions in 2021-2022, the Central Drugs Standard Control Organisation (CDSCO) accelerated its review process under the New Drugs and Clinical Trials Rules, 2019.

The 2024 surge focused heavily on popular “cocktail” drugs used for common colds, coughs, and pain relief. Notable examples include combinations like Cetirizine + Phenylephrine + Paracetamol + Zinc Gluconate. Expert committees ruled that these multi-drug formulas often provided no additional therapeutic benefit over single-ingredient medications while increasing the likelihood of adverse side effects.

Why “Irrational” Drugs are a Public Health Risk

The core issue lies in the “irrationality” of these combinations. For a drug to be rational, the ingredients must work together safely and effectively to treat a specific condition.

“This poses a serious risk to public health and safety,” stated Drugs Controller General Rajeev Raghuvanshi during a 2025 briefing. He emphasized that many of these products reached the market via state-level licenses, effectively bypassing the rigorous safety and efficacy evaluations required by the central government.

The Threat of Antimicrobial Resistance (AMR)

A 2023 World Health Organization (WHO) study revealed a startling statistic: 41.5% of antibiotic FDCs sold in India were “not recommended.” When patients take unproven combinations of antibiotics, it creates a breeding ground for “superbugs” that are resistant to treatment. Globally, AMR is linked to 1.27 million deaths annually, making the restriction of these drugs a matter of international security.

Veterinary Concerns and the “One Health” Approach

The 2025 ban on 36 veterinary drugs, including critical antimicrobials like carbapenems and antivirals like Oseltamivir, is designed to protect humans as much as animals.

“Using high-level human antibiotics in livestock can lead to resistant bacteria entering the human food chain through meat and milk,” explains a spokesperson for the One Health initiative. “Preserving these drugs for life-threatening human infections is non-negotiable.”

Expert Perspectives: A “Landmark Decision”

Medical professionals have largely lauded the move, though they caution that enforcement remains the ultimate hurdle.

Dr. Deep Dutta, a renowned endocrinologist and clinical researcher, welcomed the 2025 prohibition of 35 specific FDCs. “Irrational combinations of medicines have been correctly banned by the CDSCO,” he noted, adding a plea for vigilance: “I hope the enforcement is strict.”

The Indian Medical Association (IMA) has long advocated for these curbs, citing the “rampant self-medication” culture in India. However, the IMA also highlights a potential pitfall. While removing unsafe cocktails is necessary, the quality of the single-drug “generics” that replace them must be guaranteed. They are calling for a “one drug, one quality” standard to ensure that patient trust in the healthcare system remains intact.

What This Means for Consumers

For the average health-conscious consumer, these bans may mean that a familiar cough syrup or painkiller is no longer available at the local pharmacy.

• Check Your Labels: If you use multi-symptom relief medications, check if they contain more than three active ingredients.

• Prioritize “Singles”: Instead of a “catch-all” cold pill, experts recommend treating specific symptoms—taking paracetamol for a fever and a separate antihistamine for a runny nose.

• Consult the CDSCO List: The government maintains a public list of prohibited drugs. Patients are encouraged to use official portals or apps to verify their prescriptions.

Challenges in Enforcement and Industry Pushback

Despite the bans, “ghost” stocks often remain on shelves. MP Dr. Anand Kumar has pointed out that some manufacturers use “court stays” on writ petitions to continue selling existing inventory for months or even years after a ban is announced.

Furthermore, the pharmaceutical industry argues that FDCs improve “patient compliance”—meaning it is easier for a patient to take one pill than three. While this is true for chronic conditions like hypertension, experts counter that for acute issues like a cough or mild infection, the risks of “over-drugging” far outweigh the convenience.

Looking Ahead: A Safer Pharma Ecosystem

India’s aggressive stance signals a shift toward evidence-driven regulation. With FDCs currently making up 40-50% of the domestic pharmaceutical market, more bans are likely as the CDSCO continues its review of older formulations.

As the “Pharmacy of the World,” India’s regulatory cleanup sets a precedent for other developing nations struggling with irrational drug use. For the public, the message is clear: more ingredients do not equal better medicine.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://medicaldialogues.in/news/industry/pharma/over-200-human-and-veterinary-drugs-banned-since-2023-parliament-told-164565